Dr. Hill cited a study demonstrating that yearling buyers paid just as much for inferior horses as they did for the ones who were most successful on the track, noting that a thoroughbred's genetic class is a more accurate predictor of its eventual earnings than the price it commands in the auction ring.
Dr. Hill is the Chairman and co-founder of Equinome, which has developed state-of-the-art genomic tools to evaluate the genetic potential of thoroughbred racehorses. Based in Dublin, Equinome has identified the different sets of genetic variants critical for performance in short-distance, middle-distance, and long-distance racing, and has made this data available to thoroughbred owners, breeders, and prospective purchasers through its Speed Gene Test, which measures a DNA variant--“C” or “T”—in a gene responsible for muscle mass development.
Equinome's Elite Performance Test evaluates 80 genetic variants to measure an individual's potential racing class, ranking individuals from Class I to Class IV. In a study of 1,051 racing thoroughbreds who had been tested, Equinome found that Class I-rated horses were six times more likely to become Grade I or Grade II winners than to be non-winners, and that 46% of the Class I runners became elite (graded or listed) stakes winners.